Taipei, June 28 (CNA) The emergency use authorization (EUA) review of a COVID-19 vaccine candidate made by Taiwan-based Medigen Vaccine Biologics Corp. will likely be pushed back to late July due to missing documentation, Taiwan's Food and Drug Administration (FDA) said Monday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Taoyuan sandwich seller indicted over suspected food safety violation
03/29/2024 06:36 PM - Politics
President urges defense minister to remain after verbal resignation
03/29/2024 06:25 PM - Science & Tech
AI needed to combat disinformation as it moves to video: Taiwan expert
03/29/2024 06:07 PM - Society
TSMC employee newborns in Taiwan make up 1.8% of country's 2023 total
03/29/2024 05:44 PM - Society
Bongkrekic acid found in 2nd Taipei food poisoning victim
03/29/2024 05:08 PM